'High immunity vs. high dose’ flu vaccine for older adults
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.08.13 05:55:57
가나다라
0
NIP-driven flu vaccine market to launch vaccines targeting people aged 65 and over
CSL Seqirus puts forward high immunity vs Sanofi high dose to target the older adult vaccine market
Marketing competition between 'Fluad Quad vs Efluelda' in the private non-reimbursed vaccine market also fierce
Equipped with their respective flu vaccines specialized for people aged 65 and older, Sanofi and CSL Seqirus are seeking to expand their market share in Korea’s influenza (flu) vaccine market, which is driven by vaccines registered in the National Immunization Program (NIP).
CSL Seqirus was the first to enter this market last year, followed by Sanofi, which newly entered the market this year. The companies will face off for the first time in the 2024-25 flu season. Each is expected to target, highlighting their respective characteristics, high immunogenicity and high dose.
▲(From the left) Pic of Fluad Quadrivalent, Efluelda
According to industry sources on the 13th, ‘Efluelda,’ Sanofi’s high-dose influenza vaccine for people ag
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)